Study to Evaluate Adverse Events and Change in Disease Activity With Oral Tablets of Upadacitinib in Adult Participants With Non-Segmental Vitiligo
Public ClinicalTrials.gov record NCT04927975. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Dose-Ranging Study to Evaluate the Safety and Efficacy of Upadacitinib in Subjects With Non-Segmental Vitiligo
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
Vitiligo is a common chronic autoimmune disease that causes the body's immune system to attack its own pigment producing skin cells. This study is to evaluate how safe and effective upadacitinib is in participants with non-segmental vitiligo. Adverse effects and change in disease activity will be assessed. Upadacitinib is being evaluated for the treatment of non-segmental vitiligo. The study will enroll approximately 160 participants aged 18-65 with non-segmental vitiligo in 5 treatment arms across 35 sites worldwide. Participants will either receive study drug vs placebo oral tablets once daily (QD) for 24 weeks (Period A). In Period B (up to 52 weeks), participants who received placebo during the first 24 weeks will switch to study drug. Participants who received study drug during the first 24 weeks, will continue to receive study drug. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.
Study identification
- NCT ID
- NCT04927975
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 185 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 65 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jun 29, 2021
- Primary completion
- Jan 12, 2023
- Completion
- Aug 28, 2023
- Last update posted
- Oct 7, 2024
2021 – 2023
United States locations
- U.S. sites
- 20
- U.S. states
- 12
- U.S. cities
- 19
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of California Irvine /ID# 229390 | Irvine | California | 92697-1385 | — |
| Stanford University /ID# 228000 | Redwood City | California | 94063 | — |
| Clearlyderm Dermatology /ID# 227993 | Boca Raton | Florida | 33428 | — |
| New Horizon Research Center /ID# 229403 | Miami | Florida | 33165-3372 | — |
| Park Avenue Dermatology, PA /ID# 229400 | Orange Park | Florida | 32073 | — |
| ForCare Clinical Research /ID# 228010 | Tampa | Florida | 33613-1244 | — |
| Dawes Fretzin, LLC /ID# 227996 | Indianapolis | Indiana | 46256 | — |
| Tufts Medical Center /ID# 228087 | Boston | Massachusetts | 02111-1552 | — |
| Duplicate_UMass Chan Medical School /ID# 228066 | Worcester | Massachusetts | 01655 | — |
| Duplicate_Michigan Center for Research Company /ID# 228054 | Clarkston | Michigan | 48346 | — |
| Hamzavi Dermatology /ID# 228056 | Fort Gratiot | Michigan | 48059 | — |
| Remington-Davis Clinical Research /ID# 229401 | Columbus | Ohio | 43215 | — |
| Essential Medical Research, LLC /ID# 228074 | Tulsa | Oklahoma | 74137-2842 | — |
| Oregon Dermatology and Research Center /ID# 228007 | Portland | Oregon | 97210 | — |
| Oregon Medical Research Center /ID# 228073 | Portland | Oregon | 97223 | — |
| Duplicate_Medical University of South Carolina /ID# 228067 | Charleston | South Carolina | 29425 | — |
| International Clinical Research - Tennessee LLC /ID# 228059 | Murfreesboro | Tennessee | 37130-2450 | — |
| Bellaire Dermatology Associates /ID# 228004 | Bellaire | Texas | 77401 | — |
| University of Texas Health Science Center at Houston /ID# 229399 | Houston | Texas | 77030-1501 | — |
| Virginia Clinical Research, Inc. /ID# 228050 | Norfolk | Virginia | 23502 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 15 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04927975, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 7, 2024 · Synced Sep 10, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT04927975 live on ClinicalTrials.gov.